114522-16-6 Usage
Uses
Used in Pharmaceutical Industry:
5,6-Dihydro-5-aza-2'-deoxycytidine is used as an anti-HIV inhibitor for the treatment of HIV/AIDS. It functions as a selective mutagen that induces A-to-G and G-to-A mutations in the genome of replicating HIV, effectively halting the virus's ability to replicate and spread within the host.
As a First-in-class lethal mutagen of HIV-1, 5-AZC has demonstrated its effectiveness in combating the virus by introducing lethal mutations into its genetic material, thus preventing the production of viable viral particles. This innovative approach to HIV treatment has made 5-AZC a valuable asset in the fight against the disease.
In addition to its direct anti-HIV properties, 5-AZC has also shown potential in combination therapies, where it can be used alongside other antiretroviral drugs to enhance the overall treatment efficacy and reduce the likelihood of drug resistance development. This synergistic effect can lead to improved patient outcomes and better management of the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 114522-16-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,5,2 and 2 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 114522-16:
(8*1)+(7*1)+(6*4)+(5*5)+(4*2)+(3*2)+(2*1)+(1*6)=86
86 % 10 = 6
So 114522-16-6 is a valid CAS Registry Number.
114522-16-6Relevant articles and documents
Nucleosides and process
-
, (2008/06/13)
Novel 5,6-dihydro-syn(s)-triazine nucleosides and nucleotides and a novel process for preparing the same. The novel nucleosides and nucleotides are disclosed as active in vitro and/or in vivo against susceptible DNA viruses.
Composition of matter and process
-
, (2008/06/13)
A process for treating DNA viral diseases in humans and animals which comprises administering a therapeutic amount of a compound of the formula STR1 the compounds are formulated with pharmaceutical carriers for systemic or local means of administration. CROSS REFERENCE TO RELATED APPLICATION
Nucleosides and process
-
, (2008/06/13)
Novel 5,6-dihydro-syn(s)-triazine nucleosides and nucleotides and a novel process for preparing the same. The novel nucleosides and nucleotides are disclosed as active in vitro and/or in vivo against susceptible DNA viruses.
